Squamous Cell Carcinoma of the Larynx Clinical Trial
— STELLAROfficial title:
The STELLAR Trial: Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial
Verified date | February 2024 |
Source | Erasmus Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label, single-dose, prospective clinical trial. The study comprises 2 work packages. The main objective of work package I (WP-1) is to assess feasibility of Fluorescence imaing (FLI) during total laryngectomy (TLE) and to assess the optimal dose of the cRGD-ZW800-1. Work package II (WP-II) is designed to assess whether FLI can detect and decrease tumor positive margins after a TLE.
Status | Not yet recruiting |
Enrollment | 27 |
Est. completion date | November 2025 |
Est. primary completion date | May 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients with biopsy-proven squamous cell Laryngeal and hypopharyngeal cancer, eligible for surgical resection of the tumor by TLE; - = 18 years of age; - Written informed consent must be obtained; - Sufficient knowledge of the Dutch language to understand the informed consent form; Exclusion Criteria: - History of a clinically significant allergy or anaphylactic reactions to any of the components of the agent; - Other synchronous biopsy proven malignancies currently active, except for adequately treated in situ carcinoma of cervix and basal, squamous cell skin carcinoma, or other head- and neck squamous cell cancer; - Patients pregnant or breastfeeding; - Patients with renal insufficiency (defined as eGFR < 60); - Patients with previous kidney transplantation or a solitary functioning kidney; - Patients using medications that may significantly impair renal function (i.e. NSAIDs, particularly COX-2 inhibitors), that cannot be paused during the course of the study; - Patients with ASA classification of 4 or higher; - Patients with measured QTc of 500 ms or higher at screening; - Patients with laboratory abnormalities defined as: - Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the ULN or; - Total bilirubin above 3 times the ULN or; - Platelet count below 100 x 109/L or; - Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males). - Immuno-compromised patients who do not have the ability to respond normally to an infection due to an impaired or weakened immune system, caused by either a preexisting disease or concomitant medications; |
Country | Name | City | State |
---|---|---|---|
Netherlands | Erasmus Medical Center | Rotterdam | Zuid-Holland |
Lead Sponsor | Collaborator |
---|---|
Erasmus Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | WP-I: the optimal dose of cRGD-ZW800-1 for FLI of laryngeal and hypopharyngeal cancer | Based on the tumor-to-background ratio (TBR) on breadloaves. Higher TBRs indicate a better outcome | Up to 48 hours after administration (Depending on pathology grossing) | |
Primary | WP-II: the rate of clear tumor resection margins | Through histopathology, up to max 4 weeks post-op |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540899 -
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06137378 -
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
|
Phase 2 | |
Not yet recruiting |
NCT06380686 -
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
|
||
Not yet recruiting |
NCT05608369 -
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
|
Phase 2 | |
Withdrawn |
NCT04831450 -
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Phase 2 | |
Recruiting |
NCT06030440 -
De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03370276 -
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03114462 -
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
|
Phase 1 | |
Terminated |
NCT02464137 -
HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer
|
Phase 1 |